Focused On-demand Library for Small ribosomal subunit protein eS7

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P62081

UPID:

RS7_HUMAN

Alternative names:

40S ribosomal protein S7

Alternative UPACC:

P62081; P23821; P24818; Q57Z92; Q6IPH1

Background:

Small ribosomal subunit protein eS7, also known as 40S ribosomal protein S7, plays a crucial role in protein synthesis. It is a component of the small ribosomal subunit, essential for rRNA maturation and part of the SSU processome. This protein is involved in the intricate process of generating RNA folding, modifications, rearrangements, and cleavage, facilitating the assembly of the ribosomal subunit in the nucleolus.

Therapeutic significance:

Small ribosomal subunit protein eS7 is linked to Diamond-Blackfan anemia 8, a condition characterized by hypoplastic anemia and increased malignancy risk. Understanding the role of Small ribosomal subunit protein eS7 could open doors to potential therapeutic strategies for this congenital anomaly.